A Protocol for the Automated Assessment of Cutaneous Pathology in a Mouse Model of Hemichannel Dysfunction
Methods Mol Biol. 2024;2801:177-187. doi: 10.1007/978-1-0716-3842-2_13.ABSTRACTIn this chapter, we provide detailed instructions to perform quantitative reflectance imaging in a mouse model of a rare epidermal disorder caused by hyperactive connexin 26 hemichannels. Reflectance imaging is a versatile and powerful tool in dermatology, offering noninvasive, high-resolution insights into skin pathology, which is essential for both clinical practice and research. This approach offers several advantages and applications. Unlike traditional biopsy, reflectance imaging is noninvasive, allowing for real-time, in vivo examination o...
Source: Mol Biol Cell - April 5, 2024 Category: Molecular Biology Authors: Chiara Peres Fabio Mammano Source Type: research
Polymorphisms in the CD6-ALCAM axis may modulate psoriasis risk and outcomes
Hum Immunol. 2024 Apr 5:110797. doi: 10.1016/j.humimm.2024.110797. Online ahead of print.ABSTRACTThe fact that CD6, along with its ligand - ALCAM, plays a role in regulating T cell activation makes the genes encoding these molecules promising candidates for research in T cell-mediated diseases such as psoriasis vulgaris (PsV). Our study aimed to determine whether CD6 (rs17824933C>G, rs11230563C>T and rs12360861G>A) and ALCAM (rs6437585C>T, rs11559013G>A) polymorphisms may affect psoriasis susceptibility and severity (assessed by Psoriasis Area and Severity Index (PASI)). Moreover, the presence of HLA-C*06:02...
Source: Human Immunology - April 5, 2024 Category: Allergy & Immunology Authors: Marta Wagner Maciej Sobczy ński Andrzej Wi śniewski Łukasz Matusiak Piotr Ku śnierczyk Monika Jasek Source Type: research
Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review
CONCLUSION: This study suggested that smoking history and psoriatic skin lesions on the anterior lower legs are considered as the risk factors for the failure to achieve a PASI100 response in psoriasis patients treated with biologics.PMID:38576247 | PMC:PMC10995612 | DOI:10.5021/ad.23.074 (Source: Annals of Dermatology)
Source: Annals of Dermatology - April 5, 2024 Category: Dermatology Authors: Eun Ji Hong Hee Jung Yoon Min Jung Kwon Jae Yun Kim Jung Eun Kim Young Lip Park SangHoon Lee Youin Bae Sul Hee Lee Source Type: research
Transcriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity
Genes & Immunity, Published online: 05 April 2024; doi:10.1038/s41435-024-00271-wTranscriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity (Source: Genes and Immunity)
Source: Genes and Immunity - April 5, 2024 Category: Genetics & Stem Cells Authors: Charalabos Antonatos Georgios K. Georgakilas Evangelos Evangelou Yiannis Vasilopoulos Source Type: research
Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis
ConclusionThis study analyzed the clinical characteristics and therapeutic aspects of BLP. Compared with published studies, we have new findings, such as gender bias. Besides traditional antipsoriatic treatment, a personalized selection of biologics may also be a promising choice. Dermatologists should recognize and understand the significance of this disease, and provide patients with appropriate psychological counseling and clinical treatments. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 5, 2024 Category: Dermatology Source Type: research
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
CONCLUSION: Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.PMID:38571927 | PMC:PMC10985702 | DOI:10.1515/rir-2024-0006 (Source: Cell Research)
Source: Cell Research - April 4, 2024 Category: Cytology Authors: Marco Matucci-Cerinic Francesco Ciccia Rosario Foti Alessandro Giunta Francesco Loconsole Francesca Prignano Rossana Scrivo Giampiero Girolomoni Source Type: research
Pleural Effusion, Giardia, Adnexal Mass, Testosterone Replacement, Chronic Kidney Disease, Scalp Psoriasis
Am Fam Physician. 2024 Mar;109(3):208.NO ABSTRACTPMID:38574206 (Source: American Family Physician)
Source: American Family Physician - April 4, 2024 Category: Primary Care Source Type: research
